Where Will CRISPR Therapeutics Be in 1 Year?
The past year has been challenging for gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP). The company lagged the market as economic worries such as inflation spooked investors. Clinical-stage biotechs like CRISPR Therapeutics that aren't consistently profitable were hit especially hard. However, the biotech boasts some promising pipeline candidates, and it is looking at major catalysts that could send its stock price soaring by the end of the year. What will the next 12 months have in store for CRISPR Therapeutics?
Source Fool.com
